New Directions in Chemical Process Design 2008 Conference
10-11 April, 2008 Konzerthaus, Freiburg, Germany Organised by
avakado Conferences
Plus Chromatography Workshop 10 April, 2008 When is Preparative Chromatography Useful in Chiral Syntheses? Organised by Groupe Novasep Supported by:
New Directions in Chemical Process Design 2008 Conference Thursday 10th & Friday 11th April 2008 Conference partners The New Directions in Chemical Process Design conference is taking place with the support of BioValley, the life science cluster for the bioregions of Alsace, France; South Baden, Germany; and northwest Switzerland, with centres in Strasbourg, Freiburg and Basel. BioValley is one of the first European initiatives in the field of life sciences, and in the past 10 years has given significant emphasis and impetus to life sciences development in the tri-national European region. Today, BioValley is a unique, global, cross-border life science cluster with one of the world’s highest densities of life science activities and around 40 per cent of all international pharmaceutical companies can be found in the BioValley. sp2, the leading monthly magazine covering drug discovery and development, is published by the organisers of the conference and has a high-quality readership comprising senior R&D and commercial management personnel from pharmaceutical, biotech, speciality pharmaceutical, fine chemical and chemical technology specialist companies.
New Directions in Chemical Process Design The New Directions in Chemical Process Design conference features new technologies for pharmaceutical intermediates and ingredients, and includes presentations from industry and academe covering the application of new chemistry in the fields of chiral synthesis, aromatic compounds, catalytic processes and biocatalysis in pharmaceutical discovery, development and manufacture. Delegates who will benefit from attending the conference are senior R&D scientists, managers and decision-makers from pharmaceutical and biotechnology companies looking to develop new routes to economically and efficiently produce their developmental drug candidates.
CONFERENCE DAY ONE – Thursday, 10 April, 2008 8.00
Registration and Morning Coffee
8.50
Morning Chair’s Opening Remarks
9.00
Quality by Design, Principles and Case Studies Dr Keith DeVries – Director, Chemical Product R&D, Eli Lilly and Company
9.45
New Total Syntheses Using New Strategies and Methodologies for Rapid Construction of Molecular Complexity in Complex Alkaloid Total Synthesis Professor Mohammad Movassaghi – Firmenich Assistant Professor of Chemistry, Massachusetts Institute of Technology
10.30
Morning Coffee and Exhibition Viewing Time
10.45
Physical Organic Chemistry: An Alternative Approach To Improved Processes Dr Ian Ashworth – Team Manager, Physical Organic Chemistry Group, AstraZeneca Process R&D
11.30
Protecting-Group-Directed Ring-Closing Metathesis: The First Total Synthesis of Anti-Malarial Nonenolide Dr Mukund Chorghade – National Chemical Laboratory (Pune, India)
12.15
Lunch and Exhibition Viewing Time
13.45
Afternoon Chair’s Opening Remarks
14.00
Accelerating Biocatalytic Process Design: Integrating New Tools from Biology, Chemistry and Engineering Professor Gary J. Lye – The Advanced Centre for Biochemical Engineering, University College London
14.45
Enabling New and Efficient Processes: Searching for the Ideal Biocatalyst Dr Jürgen Eck – CSO, BRAIN Aktiengesellschaft
15.30
Scaling Biocatalytic Processes in the Pharmaceutical Industry Dr Roger Howard – Biocatalysis Centre of Emphasis, Pfizer Ltd Chemical Research and Development
16.15
Development of Scaleable Biocatalytic Processes for Pharma Intermediates Dr David Rozzell – Vice President, Enzyme Products and Services, Codexis, Inc
17.00
End of Day One Conference Session
18.00
BioFine Europe Convention Networking Reception
New Directions in Chemical Process Design 2008 Conference Thursday 10th & Friday 11th April 2008 CONFERENCE DAY TWO – Friday, 11 April, 2008 8.00
Registration and Morning Coffee
8.50
Morning Chair’s Opening Remarks
9.00
Competitive Bioprocesses for Speciality Fine Chemicals Fabrice Lefevre – CSO, LibraGen
9.45
A Technology Platform for the Discovery, Optimisation and Production of High-Value Enzymes Dr Andreas Vogel – Principal Scientist R&D, c-LEcta GmbH
10.30
Morning Coffee and Exhibition Viewing Time
10.45
Design and Exploration of Stereoselective Synthesis Routes for APIs Dr Gerjan Kemperman – Senior Development Scientist, Department of Process Chemistry, NV Organon
11.30
Commercial-scale Applications of Asymmetric Hydrogenation Technology Dr Ian Lennon – Scientist and Technology Leader, Dowpharma, Chirotech Technology Ltd
12.15
Lunch and Exhibition Viewing Time
13.45
Afternoon Chair’s Opening Remarks
14.00
P-Chiral Ligands for Asymmetric Synthesis Dr Brian Kelly – Director of Business Development, Celtic Catalysts Ltd
14.45
Process Design: Applications of Chiral Chromatography Dr Ousmane Diouf – Business Development Manager, Novasep Synthesis
15.30
Rapid Development of New Catalytic Systems for Organic Compound Synthesis Dr David Ager - Principal Scientist, DSM Pharmaceuticals, Inc
16.15
Exhibition Viewing Time and End of Conference
Comments from previous attendees at avakado Conferences meetings: “I found the conference to be useful not only from a technical aspect but it also allowed me the opportunity of quality networking with fellow chemists. The content of the presentations was outstanding!” – Paul D. May, Principal Research Scientist, KAPI Process Technology, Pfizer Global Manufacturing “An excellent conference with some ‘world-class’ presentations” – Lyn Powell, Associate Principal Scientist, Process Chemistry, AstraZeneca “This meeting was outstanding. The papers were terrific and I learned a great deal. In addition, the networking sessions were of real value. I look forward to attending another meeting in the near future.” – Distinguished Professor James M. Cook, University of Wisconsin - Milwaukee “The best I have attended for interactions between industrial and academic attendees” – Pfizer Scientist
The organisers reserve the right to amend the conference programme as circumstances dictate
New Directions in Chemical Process Design 2008 Conference Thursday 10th & Friday 11th April 2008 Top-Quality Speaker Line-up The New Directions in Chemical Process Design conference presents the latest advances in organic process chemistry for the synthesis and industrial-scale manufacture of pharmaceutical intermediates and active ingredients and features a distinguished speaker line-up with experts in the field from academia, multinational pharmaceutical and fine chemical companies, and specialist chemical technology companies. Prominent expert speakers presenting include: Dr Ian Ashworth, Team Manager, Physical Organic Chemistry Group, AstraZeneca Process R&D. Ian Ashworth gained his Degree in Chemistry from Durham University in 1990 and a DPhil at Cambridge University on ‘Intramolecular Catalysis of Phosphonoacetate Hydrolysis’. He joined Zeneca Fine Chemicals Manufacturing Organisation in 1994 where he worked in the Process Technology Department. A move into the Process Studies Group in 1995 started a career in the application of physical organic chemistry to the solution of process-based problems in the development and manufacture of both agrochemicals and fine chemicals. This continued through a number of mergers and de-mergers and culminated in the role of Leading Scientist with Syngenta. In April 2006 he joined AstraZeneca as the Team Manager of the recently formed Physical Organic Chemistry Group within the Process R&D function at AstraZeneca’s Macclesfield, UK facility. Dr David J. Ager, Principal Scientist, DSM Pharmaceuticals, Inc. David Ager received a BSc from Imperial College, London, and a PhD from the University of Cambridge. In 1977 he was awarded a Science Research Council Postdoctoral Fellowship that allowed him to collaborate with Professor Richard Cookson FRS at the University of Southampton. In 1979 he joined the faculty of the University of Liverpool as a Senior Demonstrator. This was followed by an Assistant Professor position at the University of Toledo. In 1986, he joined the NutraSweet Company’s Research and Development Group as a Monsanto Fellow. NSC Technologies was formed out of NutraSweet R&D and in 1999 was sold to Great Lakes Fine Chemicals – Dr Ager was a Fellow with GLFC, responsible for the development of new synthetic methodology. He then left GLFC and worked as a consultant on chiral and process chemistry. He joined DSM at the beginning of 2002 as the Competence Manager for homogeneous catalysis and in January 2006 moved into the role of Principal Scientist. Professor Mohammad (Mo) Movassaghi - Firmenich Assistant Professor of Chemistry, Massachusetts Institute of Technology. Mo Movassaghi carried out his undergraduate research with Professor Paul A. Bartlett at UC Berkeley where he received his BS in chemistry in 1995. He then carried out his graduate studies with Professor Andrew G. Myers at Harvard University and completed his PhD in 2001 as a Roche Predoctoral Fellow. After a DRCRF postdoctoral fellowship with Professor Eric N. Jacobsen at Harvard, he joined the faculty at MIT in 2003 where his particular interest is complex alkaloid total synthesis. The Movassaghi group’s research activities have been recognised by the Dale F. and Betty A. Frey Scholar Award of the Damon Runyon Cancer Research Foundation, Amgen New Faculty Award, Firmenich Career Development Professorship, NSF CAREER Award, Beckman Young Investigator Award, Merck Academic Development Program Award, US National Committee/IUPAC Young Observer Fellowship Award, GlaxoSmithKline Chemistry Scholar Award, Amgen Young Investigator Award, AstraZeneca Excellence in Chemistry Award, and Lilly Grantee Award. Dr Brian Kelly, Director of Business Development, Celtic Catalysts. Since founding Celtic Catalysts, Dr Kelly has been responsible for developing and implementing the corporate and scientific strategies that have taken the company from its start-up phase to its current position. He holds an Honours BSc and a PhD from University College Dublin. His PhD work focused specifically on the area of chiral catalyst discovery. Dr Kelly has also been a visiting lecturer in the Smurfit Graduate School of Business and the National University of Ireland, where he has lectured on technology management and biotechnology start-ups. He is an executive committee member of BioConnect Ireland (an independent networking organisation for individuals in the biotechnology and life science sectors in Ireland). He is also a member of the American Chemical Society and of the Royal Society of Chemistry. Dr Andreas Vogel, Principal Scientist R&D, c-LEcta GmbH. After finishing his PhD in Chemistry/Biochemistry at the University of Münster, Dr Vogel moved to the European Laboratory for Molecular Biology (EMBL) in Hamburg where he worked in the field of structural biology. He then did postdoctoral work at the Max-Planck-Institute for Coal Research in Mülheim/Ruhr joining the group of Prof. M. T. Reetz. His subjects were: new methods for enzyme optimization using directed evolution techniques, high-throughput screening, and biocatalysis. Since February 2006, Dr Vogel has worked at c-LEcta, where he is responsible for biocatalysis, enzyme engineering, and recombinant expression. Dr Ian C. Lennon, Scientist and Technology Leader, Dowpharma, Chirotech Technology Ltd. Ian Lennon graduated from the University of St. Andrews in 1985 with a BSc in Chemistry and then worked for Merck, Sharp & Dohme in Harlow, UK in drug discovery. In 1989, he left Merck to study for a PhD with Professor Steve Ley at Imperial College, London. In 1993, Dr Lennon joined Chiroscience and in 1995 he carried out a secondment with Professor Barry Trost at Stanford University. He was Head of Collaborative Research for Chirotech between 1997 and 2001. Chirotech was acquired by The Dow Chemical Company in 2001 and is now part of Dowpharma. Dr Lennon is currently a Scientist and Technology leader for Chemocatalysis and is involved with the development of asymmetric chemocatalysis capability, promotion of chiral technology and with the management of customer projects. He is an Editorial Advisory Board member of Organic Process Research & Development and Chimica Oggi. He is an author/co-author of over 60 technical publications and 6 patents. Dr Fabrice Lefevre, Chief Scientific Officer, LibraGen. Fabrice Lefevre is a biotechnology engineer and a graduate of the National Institute of Applied Sciences. He then received his PhD in molecular biology and protein engineering from the University of Toulouse. He has more than 10 years of industrial experience in enzyme discovery and protein optimisation in different fields of application, with a special focus on biocatalysis. Before joining LibraGen, he held the position of VP CSO at Protéus, a French biotechnology company focused on extremophile micro-organisms. He now leads LibraGen’s research and development programmes. He is the author of 11 papers, several book chapters, and of more than 20 patents, many of them being granted in the USA and Europe.
New Directions in Chemical Process Design 2008 Conference Thursday 10th & Friday 11th April 2008 Dr Mukund Chorghade, National Chemical Laboratory, (Pune, India). Mukund Chorghade is currently President of Chorghade Enterprises/THINQ Pharma, Inc based in Natick, Massachusetts, USA and is Chief Scientific Officer, D & O Pharmachem. He earned his BSc and MSc Degrees from the University of Pune. He earned a PhD in Organic Chemistry at Georgetown University in Washington, DC in 1982. He completed postdoctoral appointments at the University of Virginia and Harvard University, visiting scientist appointments at the University of British Columbia, Vancouver, Canada and College de France/Université Louis Pasteur and directed research groups at Dow Chemicals, Abbott Laboratories and CytoMed. He established his own enterprise as a consultant to the pharmaceutical industry in 1995. He was Vice-President, Chemical Development Sciences at Geltex/Genzyme, where he oversaw projects in chemical route selection, process development, chemical manufacturing and formulation of bulk actives to finished dosage forms. He is currently an adjunct faculty member at Harvard, Mass College of Pharmacy, University of Pune, Wellesley College, and Tufts. He is active in the American Chemical Society and IUPAC and is on the scientific advisory boards of OrgSyn Laboratories, CiVentichem and others. Dr Ousmane Diouf, Business Development Manager, Novasep Synthesis. Ousmane Diouf holds a PhD in Medicinal Chemistry along with a Master in Drug Design (ENSC Lille & Institut de Chimie Thérapeutique, Lille). After several years at UCB Pharma as Process Chemist and Global Technical Leader, he joined Groupe Novasep in 2005 as a Technical Project Manager and is now Business Development Manager for Novasep Synthesis. Dr Roger Howard, Biocatalysis Centre of Emphasis, Pfizer Ltd Chemical Research and Development. Roger Howard completed a Masters Degree in Chemistry (MChem) at the University of Manchester in 2001, undertaking a final-year project in the organic chemistry total synthesis group led by Professor E. J. Thomas. After a brief spell at financial services company KPMG, he returned to chemistry in 2002, undertaking a PhD in organic chemistry under the supervision of Professor Stanley M. Roberts at the University of Liverpool. His research led him to study the use of biotransformations in organic synthesis and in April 2006 he began his industrial career as a biotransformations scientist in the Chemical Research and Development department of Pfizer in Sandwich, UK. He continues to work as the senior UK-based member of Pfizer’s Biocatalysis Centre of Emphasis. His scientific interests include scalable biotransformations and asymmetric synthesis. Professor Gary J. Lye, Professor of Biochemical Engineering, The Advanced Centre for Biochemical Engineering, University College London. Gary Lye received his PhD in Biotechnology from the University of Reading in 1992. Between 1993 and 1996 he was successively a Research Fellow and then Lecturer in Chemical Engineering at Imperial College London and the University of Edinburgh. He joined UCL in 1996. He is currently Chair of the Biochemical Engineering Subject Group of the UK Institution of Chemical Engineers (IChemE). He has broad research interests on the application of microscale and automation techniques to the rapid design, optimisation and scale-up of bioconversion processes. He currently leads the multidisciplinary Bioconversion-Chemistry-Engineering Interface (BiCE) programme at UCL.
WORKSHOP, THURSDAY, 10 APRIL, 2008 When is Preparative Chromatography Useful in Chiral Syntheses? [Novasep logo]
Organised by Groupe Novasep
The objective of this workshop is to share experiences of preparative chromatography specialists including stationary phase suppliers, process designers and equipment manufacturers, users, CMOs and pharmaceutical manufacturing specialists. During the workshop, the benefits and limitations of chromatography technology will be discussed and demonstrated. Through presentations and case studies, participants in this workshop will understand how and where to integrate a preparative chromatography step while developing synthetic processes. This understanding is useful to chemists, scientists and engineers involved in process development in order to reduce process development time during scale-up, obtain a higher product quality, a higher productivity and/or yield, and implement a sound strategy to develop an economically advantageous first- or second-generation manufacturing process. Preparative chromatography specialists will present their approach to obtain a pure enantiomer. CMO and pharmaceutical manufacturing specialists will describe their experiences in integrating preparative chromatography at different steps in the synthesis of chiral APIs. There will be four presentations of about 20 minutes’ duration as follows: 10.00
Introduction and Welcome
10.10-10.30
Novasep Process – chromatography process design company and a supplier of chromatography and purification services. Presentation by Dr Jean Blehaut, President, Pharma Business Unit
10.30- 10.50
Chiral Technologies Europe – chiral stationary phase supplier and a purification service provider. Presentation by Dr Brian Freer, Business Development Manager
10.50-11.10
Novasep Synthesis – CMO specialised in chiral synthesis. Presentation by Dr Thierry Durand, R&D Director, Finorga SAS (part of Novasep Synthesis)
11.10-11.30
Chromatography in Practice – Presentation from a pharmaceutical manufacturing company (details to be confirmed)
11.30- 11.50
Discussion
Registration for New Directions in Chemical Process Design 10-11 April, 2008, Konzerthaus, Freiburg, Germany
Registration Form
Conference Registration includes: • Attendance at all conference sessions • A copy of the conference proceedings • Unlimited access to the BioFine Europe Exhibition • Lunch & refreshments on each day • BioFine Europe Convention Networking Reception on 10 April
DELEGATE FEES
Method of Payment
2-Day Conference – £595 or €892
Credit Card
Register 3 delegates, save 10%
Cheque Invoice Me
ALL PAYMENTS MUST BE RECEIVED BEFORE THE EVENT DATE. Confirmation of your registration will be supplied by fax or e-mail and your invoice will be sent to you by post.
First Delegate Credit Card Details Company: .............................................................................. Name:.....................................................................................
AMEX
Visa
Mastercard
Job:.........................................................................................
Card No: ..............................................................................
Title:......................................................................................
3-digit Security Code:.......................................................
Address: ...............................................................................
Expiry Date ..........................................................................
................................................................................................
Cardholders Name:...........................................................
................................................................................................
Address (if different from first delegate name): ...............................................................................................
Postcode: ............................................................................ ............................................................................................... Country:............................................................................... ............................................................................................... Email: .................................................................................... Signature: ........................................................................... Telephone. ...........................................................................
Invoice To: Mobile:.................................................................................. Fax: ........................................................................................
Name: .................................................................................... Company:..............................................................................
Second Delegate
Address (if different from first delegate name):
Name:.....................................................................................
...............................................................................................
Job Title:...............................................................................
............................................................................................... ...............................................................................................
Address: ............................................................................... Telephone: ..........................................Fax: ........................ Email: .................................................................................... Telephone. ...........................................................................
Third Delegate Name:..................................................................................... Job Title:............................................................................... Address: ............................................................................... Email: .................................................................................... Telephone. ...........................................................................
For more information contact Tom Mulligan, Conference Director, avakado Ltd, 13 Market Square, Horsham West Sussex, RH12 1EU, United Kingdom Tel: +44 (0)1403 220755 Fax: +44 (0)1403 220761 Email:
[email protected] www.biofineeurope.com
Terms and Conditions of Business Exhibition & Sponsorship opportunities Discounts. Complete the details for all three delegates and your 10% discount for the combined total will automatically be applied. The offer only applies where all delegates are booked simultaneously and at the same billing address. Attendee names can be substituted at any time prior to the conferences taking place, but please notify us of this as soon as possible. Substitutions/Cancellations. Should you be unable to attend and cancel in writing by March 10, 2008 at the latest, avakado Conferences will refund your registration fee less £200 to cover administration costs. It is regretted that after March 10, 2008 refunds are not possible. Substitutions can be made at any time. Change of Details. If your address used on this brochure is incorrect or if you do not wish to receive any further information from us, please contact us on +44-(0)1403 220760. Data Protection. The personal information given on this form may be used by avakado Conferences for marketing purposes. If you DO NOT wish this information to be disclosed to any third parties, please tick this box. Venue Information The conference is taking place at the excellent facilities of the Kongresszentrum Konzerthaus Freiburg, located in the heart of the city in Konrad-Adenauer-Platz. A shuttle bus service operates directly from EuroAirport Basel Mulhouse Freiburg to the Konzerthaus. In addition, the venue is situated just 50 metres from Freiburg’s Central Railway Station, and it also has 1,000 parking spaces. Hotel Information The Novotel Freiburg Hotel is attached to the convention venue. To reserve your accommodation or for further information go to www.biofineeurope.com and click on the Travel & Stay link. The Exhibition Now in its fifth year, the BioFine Europe Exhibition has become an important annual event for drug discovery and development. Leading companies will be showcasing their products and services to support drug discovery and development. Entrance to the BioFine Europe Exhibition is free of charge to all registered conference attendees. For further information visit www.biofineeurope.com
